Book chapter
The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities
PI3K-mTOR in Cancer and Cancer Therapy, pp.263-289
Cancer Drug Discovery and Development, Springer International Publishing
06/11/2016
Abstract
Despite the recent development of new and improved surveillance and treatment strategies, lethal prostate cancer (PCa) phenotypes with castration resistance (CRPC) and metastatic lesions remain poorly understood. Evidence is emerging for the key role of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway in CRPC, which is prevalently dysregulated in advanced PCa. Preclinical studies have revealed a mechanistic interplay between the PI3K/AKT/mTOR pathway and androgen receptor (AR) signaling, a master regulator governing PCa development and progression. The significance of the PI3K/AKT/mTOR pathway in integrating growth signals from crucial cellular events such as protein synthesis, energy metabolism, and cell proliferation and differentiation provides a clear rationale for the development of PI3K/mTOR inhibitors targeting this pathway. Relevant clinical trials offer great potential for clinical benefit. Here, we review the role of the PI3K/AKT/mTOR pathway in PCa and discuss the development and use of pathway inhibitors as single or combined therapies, and highlight ongoing clinical trials for the treatment of PCa.
Metrics
14 Record Views
Details
- Title
- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities
- Creators
- Jason Boyang Wu - Washington State University, Pharmaceutical Sciences, Department ofLeland W.K Chung - Cedars-Sinai Medical Center
- Publication Details
- PI3K-mTOR in Cancer and Cancer Therapy, pp.263-289
- Academic Unit
- Pharmacy and Pharmaceutical Sciences, College of
- Series
- Cancer Drug Discovery and Development
- Publisher
- Springer International Publishing; Cham
- Identifiers
- 99900620488601842
- Language
- English
- Resource Type
- Book chapter